#Switzerland #Heart Failure #Zug #Berlin Heals #Rob ten Hoedt

Berlin Heals Welcomes Rob ten Hoedt as New Chairman of the Board

Berlin Heals Holding AG, a prominent player in the medical technology industry, has recently announced the appointment of Rob ten Hoedt as its new Chairman of the Board of Directors. This leadership transition comes at a crucial time for the company as it aims to enhance its innovative treatment solutions for heart failure, one of the leading health challenges worldwide.

A Significant Appointment

Rob ten Hoedt's appointment was met with enthusiasm by the company's co-founder Marko Bagaric, who expressed confidence in ten Hoedt’s breadth of expertise and influence in the healthcare sector. With over 30 years of experience under his belt, ten Hoedt has a proven track record in medical technology. His most recent role was as Executive Vice President and President of Global Regions at Medtronic, where he played an instrumental role in steering the company toward significant advancements in medical devices.

Prior to his successful tenure at Medtronic, ten Hoedt held various senior leadership positions at Medtronic SQDM, Vitatron, and Urologix. He is not only well-educated—holding a degree in Commercial Economy and a Master's in Marketing—but is also actively involved in other boards, including Medmix and Onward Medical. His multifaceted experience is expected to bring a wealth of knowledge and fresh perspectives to Berlin Heals.

Vision for Change

In his own words, ten Hoedt expressed his eagerness to join Berlin Heals, stating, "I am very excited to join the Board of Directors at Berlin Heals Holding AG and to contribute to its revolutionary new therapy in Heart Failure." His vision aligns seamlessly with the company’s mission to bring the life-saving benefits of its flagship product, the C-MIC device, to patients around the world.

C-MIC Therapy, or Cardiac Microcurrent Therapy, represents a pioneering advancement in treating heart failure, connecting an implantable generator to electrodes that administer a continuous microcurrent to the affected heart. Initial studies have shown promising results in restoring cardiac functions and alleviating symptoms, making this innovation highly anticipated among medical professionals.

The Global Heart Failure Challenge

Heart failure is a condition where the heart's ability to pump blood is compromised, often leading to distressing symptoms such as fatigue and shortness of breath. This global pandemic affects over 64 million individuals, and alarming projections indicate that by 2050, the costs associated with heart failure care could reach an unprecedented $858 billion annually. With these staggering statistics, the urgency for innovative solutions within the healthcare system has never been greater.

The strategic direction provided by ten Hoedt is integral not just for Berlin Heals but also for the wider healthcare community striving to address the complexities of heart failure. John Brumfield, the CEO of Berlin Heals, emphasized the importance of leadership in navigating this pivotal year and highlighted ten Hoedt's genuine enthusiasm for innovation. His insights and leadership are geared towards shaping Berlin Heals' future strategies and driving growth that will ultimately benefit countless patients.

Looking Ahead

As Berlin Heals enters a transformative phase with ten Hoedt at the helm, stakeholders are optimistic about the innovations to come. With the support of a leader distinguished by deep expertise in healthcare and a passion for innovation, the company is well-positioned to advance its groundbreaking therapies and fulfill its mission of improving patient outcomes. Together with ten Hoedt, Berlin Heals is poised to make lasting contributions to the field of heart health, striving for a future where heart failure no longer claims as many lives.

Berlin Heals Holding AG, based in Zug, Switzerland, is committed to developing cutting-edge treatment options for heart failure, aiming for a profound impact on patients’ lives through their pioneering C-MIC device and ongoing research initiatives. Stay tuned for more updates on their journey and advancements in this life-critical sector.